Anixa Biosciences, Inc.
NASDAQ:ANIX · NASDAQ Capital Market
-$0.01 today
Vol 0.24M · Avg 0.11M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-72.1%
avg -132.1%
ROIC
-82.7%
avg -99.5%
ROA
-68.0%
avg -83.2%
Analysis
ROA is currently the strongest return metric at -68.0% versus its period average of -83.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Amit Kumar | Chief Executive Officer, Chairman & Co-Chair of CBAB | $1.42M | — | 62 | $350,000.00 | 1.03% |
Michael J. Catelani | President, Chief Operating Officer, Chief Financial Officer & Corporate Secretary | $734,155.00 | — | 59 | $175,000.00 | 0.51% |
Pamela D. Garzone | Chief Development Officer & Chair Breast Cancer Clinical Advisory Board | — | — | 71 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
6
$141,100.00
Sells
0
$0.00
Net Sentiment
+$141,100.00
Net buying
Most Active
Baskies Arnold M
2 transactions
Analysis
Insiders reported 6 buys worth $141,100.00 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $141,100.00. Baskies Arnold M was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +114.3% | +15.7% (15yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +114.3% over three years. Forward estimates point to Revenue at +15.7% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Opus Genetics, Inc.
NASDAQ:IRD
$328.84M
Spero Therapeutics, Inc.
NASDAQ:SPRO
$165.02M
TuHURA Biosciences, Inc.
NASDAQ:HURA
$147.74M
Acumen Pharmaceuticals, Inc.
NASDAQ:ABOS
$143.56M
Agenus Inc.
NASDAQ:AGEN
$137.42M
Seer, Inc.
NASDAQ:SEER
$94.57M
Entera Bio Ltd.
NASDAQ:ENTX
$60.63M
Inovio Pharmaceuticals, Inc.
NASDAQ:INO
$58.95M
Actuate Therapeutics Inc
ACTU
$48.33M
VistaGen Therapeutics, Inc.
VTGN
$18.88M
Who manages ANIX?
Anixa Biosciences, Inc. (ANIX) lists 3 active executives. The top listed executive is Pamela D. Garzone, Chief Development Officer & Chair Breast Cancer Clinical Advisory Board.
Are ANIX insiders buying or selling?
Recent insider activity shows net buying of $39.60M.
Explore More
Continue the stock analysis
Jump to another research area for this company.